These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Bhat VK; Kerr BD; Flatt PR; Gault VA Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155 [TBL] [Abstract][Full Text] [Related]
27. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Gault VA; Kerr BD; Harriott P; Flatt PR Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446 [TBL] [Abstract][Full Text] [Related]
28. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410 [TBL] [Abstract][Full Text] [Related]
29. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458 [TBL] [Abstract][Full Text] [Related]
30. A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. Tatarkiewicz K; Hargrove DM; Jodka CM; Gedulin BR; Smith PA; Hoyt JA; Lwin A; Collins L; Mamedova L; Levy OE; D'Souza L; Janssen S; Srivastava V; Ghosh SS; Parkes DG Diabetes Obes Metab; 2014 Jan; 16(1):75-85. PubMed ID: 23859463 [TBL] [Abstract][Full Text] [Related]
31. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores. Martin CM; Irwin N; Flatt PR; Gault VA Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200 [TBL] [Abstract][Full Text] [Related]
32. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. O'Harte FP; Mooney MH; Kelly CM; Flatt PR J Endocrinol; 2000 Jun; 165(3):639-48. PubMed ID: 10828847 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. Irwin N; McClean PL; Flatt PR J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662 [TBL] [Abstract][Full Text] [Related]